Aim: In an earlier study (study I) we had calculated the costs for FDG-PET investigations with our satellite concept (19). 433 patients were included in the study. Compared to the general indications for PET examinations the proportions of investigations were somewhat untypical: Both parameters have changed actually.
View Article and Find Full Text PDFAim: One of the main arguments against the acceptance and introduction of FDG PET as a regular benefit in the statutory Medical Insurance system in Germany are its (alleged) high costs. The aim of the present study has been to determine empirically over a period of twelve months the costs of FDG PET, making use of a satellite concept.
Methods: Documentation on performance and consumption data has been assembled for purposes of cost analysis.
To date, positron emission tomography (PET) is the most powerful tool for the non-invasive study of biochemical processes. Besides its usefulness for basic research PET has been proven to be superior to conventional diagnostic methods in several clinical indications. However, the introduction of PET into clinical practice has been hindered considerably by its costs.
View Article and Find Full Text PDF